Journal of Antimicrobial Chemotherapy (2000) 45, 191-203
© 2000 The British Society for Antimicrobial Chemotherapy
The Alexander Project 1996–1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections
GR Micro Ltd, 7–9 William Road, London NW1 3ER, UK
The Alexander Project was established in 1992 to examine antimicrobial susceptibilities of bacterial isolates from community-acquired infections of the lower respiratory tract. Testing of a range of compounds was undertaken in a central laboratory. From 1992 to 1995, isolates were collected from geographically separated areas in countries in the European Union and various states in the USA. In 1996, the study was extended to include centres in Mexico, Brazil, Saudi Arabia, South Africa, Hong Kong and other European countries not included previously. Data generated by the project during 1996–1997 confirm France and Spain as European centres with high rates of resistance to penicillin among isolates of Streptococcus pneumoniae. Both intermediate (MIC 0.12–1 mg/L) and resistant (MIC 2 mg/L) phenotypes are present. Combined resistance rates (intermediate and resistant) were 
50% in 1997. Combined resistance rates in excess of 20% were found in the Republic of Ireland, Portugal, the Slovak Republic and Hungary. Penicillin resistance continues to evolve in the USA, with combined resistance rates of 16.4% (1996) and 18.6% (1997). In the new, non-European centres, e.g. Mexico and, in particular, Hong Kong (where resistant strains accounted for 50% of all isolates of S. pneumoniae in 1996 and 55.5% in 1997), there are centres where rates of resistance are high. Macrolide resistance is increasing generally among both penicillin-resistant and penicillin-susceptible isolates of S. pneumoniae. There is variation between countries, and in four out of the 16 centres for which both 1996 and 1997 data are available, rates of macrolide resistance have fallen. Overall, the percentage of S. pneumoniae strains that is resistant to macrolides exceeds the percentage that is resistant to penicillin. In 1996, 16.5% of all S. pneumoniae isolates were resistant to macrolides compared with 10.4% resistant to penicillin, and in 1997 respective rates were 21.9% and 14.1%. ß-Lactamase production was the principal mechanism of resistance observed among isolates of Haemophilus influenzae. However, considerable variation in the percentage of isolates producing ß-lactamase (0–37.1%) was observed within this species. Within Europe, in the Republic of Ireland, France and Belgium, more than 15% of isolates were ß-lactamase producers. In Spain rates were as high as 31.7%. Outside Europe and the USA high rates were described in Mexico (25%), Saudi Arabia (27.9%, 16.7%) and Hong Kong (37.1%, 28.9%). Of H. influenzae from the USA, 30.4% were ß-lactamase producers in 1996 and 23.3% in 1997. ß-Lactamase production among isolates of Moraxella catarrhalis was observed in >90% of the isolates tested in 1996 and 1997.
* Corresponding author. Tel: +44-171-388-7320; Fax: + 44-171-388-7324; E-mail: gr.micro{at}dial.pipex.com
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B M Roede, P Bresser, P J E Bindels, A Kok, M Prins, G t. Riet, R B Geskus, R M C Herings, and J M Prins Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study Thorax, November 1, 2008; 63(11): 968 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Farrell, D. Felmingham, J. Shackcloth, L. Williams, K. Maher, R. Hope, D. M. Livermore, R. C. George, G. Brick, S. Martin, et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007 J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii87 - ii95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Morrissey, K. Maher, L. Williams, J. Shackcloth, D. Felmingham, R. Reynolds, and on behalf of the BSAC Working Parties on Resistanc Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007 J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii97 - ii103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gracia, C. Diaz, P. Coronel, M. Gimeno, R. Garcia-Rodas, G. del Prado, L. Huelves, V. Ruiz, P. L. Naves, M. C. Ponte, et al. Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005-06: results of the Cefditoren Surveillance Study J. Antimicrob. Chemother., May 1, 2008; 61(5): 1180 - 1181. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Homma, T. Hori, G. Sugimori, and Y. Yamano Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae Antimicrob. Agents Chemother., November 1, 2007; 51(11): 3810 - 3815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Isozumi, Y. Ito, T. Ishida, M. Osawa, T. Hirai, I. Ito, K. Maniwa, M. Hayashi, H. Kagioka, M. Hirabayashi, et al. Genotypes and Related Factors Reflecting Macrolide Resistance in Pneumococcal Pneumonia Infections in Japan J. Clin. Microbiol., May 1, 2007; 45(5): 1440 - 1446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. el Moussaoui, C. A J M de Borgie, P. van den Broek, W. N Hustinx, P. Bresser, G. E L van den Berk, J.-W. Poley, B. van den Berg, F. H Krouwels, M. J M Bonten, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ, June 10, 2006; 332(7554): 1355 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Brook and J. N. Hausfeld Effect of telithromycin and azithromycin on nasopharyngeal bacterial flora in patients with acute maxillary sinusitis. Arch Otolaryngol Head Neck Surg, April 1, 2006; 132(4): 442 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Granger, G. Boily-Larouche, P. Turgeon, K. Weiss, and M. Roger Molecular characteristics of pbp1a and pbp2b in clinical Streptococcus pneumoniae isolates in Quebec, Canada J. Antimicrob. Chemother., January 1, 2006; 57(1): 61 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Woodhead, F. Blasi, S. Ewig, G. Huchon, M. Leven, A. Ortqvist, T. Schaberg, A. Torres, G. van der Heijden, and T. J. M. Verheij Guidelines for the management of adult lower respiratory tract infections Eur. Respir. J., December 1, 2005; 26(6): 1138 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Farrell, I. Morrissey, S. Bakker, S. Buckridge, and D. Felmingham Global distribution of TEM-1 and ROB-1 {beta}-lactamases in Haemophilus influenzae J. Antimicrob. Chemother., October 1, 2005; 56(4): 773 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Fogarty, R. de Wet, L. Mandell, J. Chang, M. Rangaraju, and R. Nusrat Five-Day Telithromycin Once Daily Is as Effective as 10-Day Clarithromycin Twice Daily for the Treatment of Acute Exacerbations of Chronic Bronchitis and Is Associated With Reduced Health-Care Resource Utilization Chest, October 1, 2005; 128(4): 1980 - 1988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Easton, A. Smith, S. G. Gallego, A. R. Foxwell, A. W. Cripps, and J. M. Kyd Characterization of a Novel Porin Protein from Moraxella catarrhalis and Identification of an Immunodominant Surface Loop J. Bacteriol., September 15, 2005; 187(18): 6528 - 6535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Lee and B. W. Y. Young Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae J. Antimicrob. Chemother., September 1, 2005; 56(3): 603 - 605. [Full Text] [PDF]
|
|
|
|
 |
|
 D J Farrell, S G Jenkins, and R R Reinert Global distribution of Streptococcus pneumoniae serotypes isolated from paediatric patients during 1999-2000 and the in vitro efficacy of telithromycin and comparators J. Med. Microbiol., November 1, 2004; 53(11): 1109 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sulikowska, P. Grzesiowski, E. Sadowy, J. Fiett, and W. Hryniewicz Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Isolated from the Nasopharynges of Asymptomatic Children and Molecular Analysis of S. pneumoniae and H. influenzae Strain Replacement in the Nasopharynx J. Clin. Microbiol., September 1, 2004; 42(9): 3942 - 3949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Garcia-Rey, A. Fenoll, L. Aguilar, and J. Casal Effect of social and climatological factors on antimicrobial use and Streptococcus pneumoniae resistance in different provinces in Spain J. Antimicrob. Chemother., August 1, 2004; 54(2): 465 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Bean, R. B. Ikram, and J. D. Klena Molecular characterization of penicillin non-susceptible Streptococcus pneumoniae in Christchurch, New Zealand J. Antimicrob. Chemother., July 1, 2004; 54(1): 122 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Walsh, F. Carnegy, J. Willcock, and S. Amyes Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae J. Antimicrob. Chemother., May 1, 2004; 53(5): 793 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Harnett, A. P. Fraise, J. M. Andrews, G. Jevons, N. P. Brenwald, and R. Wise Comparative study of the in vitro activity of a new fluoroquinolone, ABT-492 J. Antimicrob. Chemother., May 1, 2004; 53(5): 783 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. File Jr, J. Garau, F. Blasi, C. Chidiac, K. Klugman, H. Lode, J. R. Lonks, L. Mandell, J. Ramirez, and V. Yu Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia Chest, May 1, 2004; 125(5): 1888 - 1901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Muller-Serieys, J. Andrews, F. Vacheron, and C. Cantalloube Tissue kinetics of telithromycin, the first ketolide antibacterial J. Antimicrob. Chemother., February 1, 2004; 53(2): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Reynolds, J. Shackcloth, D. Felmingham, A. MacGowan, and on behalf of the BSAC Extended Working Party on Re Antimicrobial susceptibility of lower respiratory tract pathogens in Great Britain and Ireland 1999-2001 related to demographic and geographical factors: the BSAC Respiratory Resistance Surveillance Programme J. Antimicrob. Chemother., December 1, 2003; 52(6): 931 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Matic, B. Bozdogan, M. R. Jacobs, K. Ubukata, and P. C. Appelbaum Contribution of {beta}-lactamase and PBP amino acid substitutions to amoxicillin/clavulanate resistance in {beta}-lactamase-positive, amoxicillin/clavulanate-resistant Haemophilus influenzae J. Antimicrob. Chemother., December 1, 2003; 52(6): 1018 - 1021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Buxbaum, S. Forsthuber, W. Graninger, and A. Georgopoulos Comparative activity of telithromycin against typical community-acquired respiratory pathogens J. Antimicrob. Chemother., September 1, 2003; 52(3): 371 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Clark and E. Langston Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting Mayo Clin. Proc., September 1, 2003; 78(9): 1113 - 1124. [Abstract] [PDF]
|
|
|
|
|
|
J.-C. Galan, M.-I. Morosini, M.-R. Baquero, M. Reig, and F. Baquero Haemophilus influenzae blaROB-1 Mutations in Hypermutagenic {Delta}ampC Escherichia coli Conferring Resistance to Cefotaxime and {beta}-Lactamase Inhibitors and Increased Susceptibility to Cefaclor Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2551 - 2557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Jacobs, D. Felmingham, P. C. Appelbaum, R. N. Gruneberg, and the Alexander Project Group The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents J. Antimicrob. Chemother., August 1, 2003; 52(2): 229 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Berghmans, J.-P. Sculier, and J. Klastersky A Prospective Study of Infections in Lung Cancer Patients Admitted to the Hospital Chest, July 1, 2003; 124(1): 114 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Singer, I. Harding, M. R. Jacobs, and D. H. Jaffe Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model J. Antimicrob. Chemother., May 1, 2003; 51(5): 1269 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L D Liebowitz, M Slabbert, and A Huisamen National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents J. Clin. Pathol., May 1, 2003; 56(5): 344 - 347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Morrissey, D. J. Farrell, S. Bakker, S. Buckridge, and D. Felmingham Molecular Characterization and Antimicrobial Susceptibility of Fluoroquinolone-Resistant or -Susceptible Streptococcus pneumoniae from Hong Kong Antimicrob. Agents Chemother., April 1, 2003; 47(4): 1433 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Fogarty, S. Kohno, P. Buchanan, M. Aubier, and M. Baz Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin J. Antimicrob. Chemother., April 1, 2003; 51(4): 947 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vaccheri, L. Bjerrum, D. Resi, U. Bergman, and N. Montanaro Antibiotic prescribing in general practice: striking differences between Italy (Ravenna) and Denmark (Funen) J. Antimicrob. Chemother., December 1, 2002; 50(6): 989 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J. CANT, S.B. GORDON, R.C. READ, C.A. HART, and C. WINSTANLEY Respiratory infections: Proceedings of the Eighth Liverpool Tropical School Bayer Symposium of Microbial Disease held on 3 February 2001 J. Med. Microbiol., November 1, 2002; 51(11): 903 - 914. [Full Text] [PDF]
|
|
|
|
|
|
D. Croisier, P. Chavanet, C. Lequeu, A. Ahanou, A. Nierlich, C. Neuwirth, L. Piroth, M. Duong, M. Buisson, and H. Portier Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones J. Antimicrob. Chemother., September 1, 2002; 50(3): 349 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Clark, B. Bozdogan, M. Peric, B. Dewasse, M. R. Jacobs, and P. C. Appelbaum In Vitro Selection of Resistance in Haemophilus influenzae by Amoxicillin-Clavulanate, Cefpodoxime, Cefprozil, Azithromycin, and Clarithromycin Antimicrob. Agents Chemother., September 1, 2002; 46(9): 2956 - 2962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Jones, J. A. Karlowsky, R. Blosser-Middleton, I. Critchley, C. Thornsberry, and D. F. Sahm Relationship between Antibiotic Resistance in Streptococcus pneumoniae and That in Haemophilus influenzae: Evidence for Common Selective Pressure Antimicrob. Agents Chemother., September 1, 2002; 46(9): 3106 - 3107. [Full Text] [PDF]
|
|
|
|
|
|
M. Woodhead Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Eur. Respir. J., July 1, 2002; 20(36_suppl): 20S - 27s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nagai, P. C. Appelbaum, T. A. Davies, L. M. Kelly, D. B. Hoellman, A. T. Andrasevic, L. Drukalska, W. Hryniewicz, M. R. Jacobs, J. Kolman, et al. Susceptibilities to Telithromycin and Six Other Agents and Prevalence of Macrolide Resistance Due to L4 Ribosomal Protein Mutation among 992 Pneumococci from 10 Central and Eastern European Countries Antimicrob. Agents Chemother., February 1, 2002; 46(2): 371 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ball, F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D. E. Low, E. Rubinstein, R. Wise, and T. Consensus Group on Resistance and Prescribing in R Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence J. Antimicrob. Chemother., January 1, 2002; 49(1): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Verduin, C. Hol, A. Fleer, H. van Dijk, and A. van Belkum Moraxella catarrhalis: from Emerging to Established Pathogen Clin. Microbiol. Rev., January 1, 2002; 15(1): 125 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. McGee, C. E. Goldsmith, and K. P. Klugman Fluoroquinolone resistance among clinical isolates of Streptococcus pneumoniae belonging to international multiresistant clones J. Antimicrob. Chemother., January 1, 2002; 49(1): 173 - 176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Garcia-Rey, L. Aguilar, F. Baquero, J. Casal, and R. Dal-Re Importance of Local Variations in Antibiotic Consumption and Geographical Differences of Erythromycin and Penicillin Resistance in Streptococcus pneumoniae J. Clin. Microbiol., January 1, 2002; 40(1): 159 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-I. Morosini, R. Canton, E. Loza, M.-C. Negri, J.-C. Galan, F. Almaraz, and F. Baquero In Vitro Activity of Telithromycin against Spanish Streptococcus pneumoniae Isolates with Characterized Macrolide Resistance Mechanisms Antimicrob. Agents Chemother., September 1, 2001; 45(9): 2427 - 2431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. File Jr, B. Schlemmer, J. Garau, M. Cupo, C. Young, and the 049 Clinical Study Group Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin J. Antimicrob. Chemother., July 1, 2001; 48(1): 67 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Chopra and M. Roberts Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance Microbiol. Mol. Biol. Rev., June 1, 2001; 65(2): 232 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, M. Warner, R. C. George, and D. M. Livermore Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales J. Antimicrob. Chemother., April 1, 2001; 47(4): 411 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cizman, M. Pokorn, K. Seme, A. Orazem, and M. Paragi The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens J. Antimicrob. Chemother., April 1, 2001; 47(4): 475 - 477. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Maskell, A. M. Sefton, and L. M. C. Hall Multiple Mutations Modulate the Function of Dihydrofolate Reductase in Trimethoprim-Resistant Streptococcus pneumoniae Antimicrob. Agents Chemother., April 1, 2001; 45(4): 1104 - 1108. [Abstract] [Full Text]
|
|
|
|
|
|
R. Dagan, K. P. Klugman, W. A. Craig, and F. Baquero Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy J. Antimicrob. Chemother., February 1, 2001; 47(2): 129 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K STEELE, G GORMLEY, and C H WEBB Management of adult lower respiratory tract infection in primary care Thorax, February 1, 2001; 56(2): 87 - 88. [Full Text]
|
|
|
|
|
|
S. Miyazaki, T. Hosoyama, N. Furuya, Y. Ishii, T. Matsumoto, A. Ohno, K. Tateda, and K. Yamaguchi In Vitro and In Vivo Antibacterial Activities of L-084, a Novel Oral Carbapenem, against Causative Organisms of Respiratory Tract Infections Antimicrob. Agents Chemother., January 1, 2001; 45(1): 203 - 207. [Abstract] [Full Text]
|
|
|
|
|
|
K.-S. Paek, M.-Y. Kim, C.-S. Lee, and H. Youn In Vitro and In Vivo Activities of LB 10827, a New Oral Cephalosporin, against Respiratory Pathogens Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3272 - 3277. [Abstract] [Full Text]
|
|